The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

Completed

Looking for future studies?

Key information

Conditions

Osteoporosis Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Tuen Mun Hospital

Hong Kong, China

About this study

We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.
Age>=18 years and <75 years.

Exclusion criteria

Pregnant or lactating women.
Uncorrected hypocalcemia.
History of esophageal stricture.
Previous intolerance or hypersenstivity to biphosphonates.

Treatment and study plan

risedronate

Drug

Primary outcomes

bone mineral density

Secondary outcomes

Adverse events, new vertebral fractures

Sponsors and collaborators

Lead sponsor

Tuen Mun Hospital

Other Gov

Registry information

Important dates

Study start: 2004
Study completion: 2007
First posted: Sep 6, 2006
Registry last updated: Sep 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed